Nivolumab for newly and recurrent glioblastoma multiforme treatment: A systematic review and meta-analysis

Objective We conducted a systematic review and meta-analysis aiming to assess the efficacy and safety of Nivolumab treatment in patients with newly diagnosed and recurrent glioblastoma multiforme (GBM). Data sources Our study followed the guidelines outlined in the preferred reporting items for syst...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Oncology Pharmacy Practice 2023-10, Vol.29 (7), p.1736-1747
Main Authors: Araujo Moura, Alexandre Wendell, da Silva Rodrigues, Sirlene, de Oliveira, Taciana Freire, Lobato, Beatriz Marques, Pereira Cerize, Natalia Neto, Léo, Patricia
Format: Article
Language:English
Subjects:
Brain cancer
Glioblastoma
Immunotherapy
Meta-analysis
Monoclonal antibodies
Survival
Systematic review
Targeted cancer therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective We conducted a systematic review and meta-analysis aiming to assess the efficacy and safety of Nivolumab treatment in patients with newly diagnosed and recurrent glioblastoma multiforme (GBM). Data sources Our study followed the guidelines outlined in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) recommendations. The protocol for this review can be found in the International Prospective Register of Systematic Reviews Database (CRD42022340071). We performed searches on the Medline, PubMed, Embase, Scopus, and Web of Science databases. Data summary A total of 545 studies were identified through our comprehensive search across the five databases (PubMed: 78, Embase: 82, Medline: 173, Scopus: 138, Web of Science: 74). After conducting a thorough analysis, our meta-analysis indicated that treatment with Nivolumab led to improved overall survival (OS) outcomes in newly diagnosed glioblastoma patients, as evidenced by a prolonged median OS based on trial data. However, there was no significant beneficial effect observed in terms of median progression-free survival (PFS), as well as OS at 6, 12, and 24 months. Furthermore, our results demonstrated no efficacy of Nivolumab in the treatment of recurrent GBM patients. Conclusions In conclusion, Nivolumab demonstrated promising results that warrant further investigation for its use in newly diagnosed glioblastoma patients. However, its effectiveness was not observed in the context of recurrent GBM.
ISSN:1078-1552
1477-092X
DOI:10.1177/10781552231190104